XBiotech Form 4: 56,000 director options, vesting at 4 and 10 months

Q: What did XBiotech (XBIT) report on this Form 4?

A grant of 56,000 nonstatutory director stock options at an exercise price of $2.64 per share on 10/01/2025 .

Q: What is the vesting schedule for the XBIT options granted?

They vest in two equal portions at four months and ten months from the October 1, 2025 grant date.

Q: When do the granted options expire for XBiotech (XBIT)?

The options expire on October 1, 2035 .

Q: How many derivative securities are beneficially owned after the transaction?

The reporting person beneficially owned 56,000 derivative securities following the transaction.

Q: Under which plan were the XBIT options granted?

The options were granted under the company’s 2025 Equity Incentive Plan .

Q: What is the underlying security for these options?

Each option is for Common Stock of XBiotech Inc.

Q: Who is the reporting person and their relationship to XBiotech (XBIT)?

The Form 4 was signed by Tevi Troy , who is listed as a Director .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

XBiotech Inc. filed a Form 4 reporting a director stock option grant. On October 1, 2025, the reporting person received 56,000 nonstatutory options with a per‑share exercise price of $2.64 under the company’s 2025 Equity Incentive Plan.

The options vest in two equal portions at four months and ten months from the grant date and expire on October 1, 2035. Following the transaction, 56,000 derivative securities were beneficially owned directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Troy Tevi David

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option	56,000	$0.00	--

Holdings After Transaction: Director Stock Option — 56,000 shares (Direct)

Footnotes (1)

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/12/2025 - 09:51 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Troy Tevi David

(Last)

(First)

(Middle)

11816 KEMP MILL ROAD

(Street)

SILVER SPRING

20902

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
XBiotech Inc. [ XBIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Director Stock Option	$2.64	10/01/2025		A		56,000		02/01/2026	10/01/2035	Common Stock	56,000	$0	56,000	D

Explanation of Responses:

Remarks:

On October 1, 2025 (the Grant Date) the reporting person was granted nonstatutory stock options (the Options) under the Company's 2025 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in two equal portions at four month and ten month from the Grant Date with an expiry of ten years from the Grant Date.

	Tevi Troy	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did XBiotech (XBIT) report on this Form 4?

A grant of 56,000 nonstatutory director stock options at an exercise price of $2.64 per share on 10/01/2025.

What is the vesting schedule for the XBIT options granted?

They vest in two equal portions at four months and ten months from the October 1, 2025 grant date.

When do the granted options expire for XBiotech (XBIT)?

The options expire on October 1, 2035.

How many derivative securities are beneficially owned after the transaction?

The reporting person beneficially owned 56,000 derivative securities following the transaction.

Under which plan were the XBIT options granted?

The options were granted under the company’s 2025 Equity Incentive Plan.

What is the underlying security for these options?

Each option is for Common Stock of XBiotech Inc.

Who is the reporting person and their relationship to XBiotech (XBIT)?

The Form 4 was signed by Tevi Troy, who is listed as a Director.